NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.80 0.00 (0.00 %) (As of 07/16/2018 03:00 AM ET)Previous Close$1.80Today's Range$1.75 - $1.8052-Week Range$1.20 - $3.75Volume149,707 shsAverage Volume224,127 shsMarket Capitalization$102.89 millionP/E RatioN/ADividend YieldN/ABeta1.02 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Receive AST News and Ratings via Email Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSEAMERICAN:AST CUSIPN/A Webasteriasbiotherapeutics.com Phone+1-510-4563805 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-403.38% Return on Equity-79.80% Return on Assets-59.45% Miscellaneous EmployeesN/A Outstanding Shares55,010,000Market Cap$102.89 Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions What is Asterias Biotherapeutics' stock symbol? Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST." How were Asterias Biotherapeutics' earnings last quarter? Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.03. The biotechnology company had revenue of $0.48 million for the quarter. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History. When is Asterias Biotherapeutics' next earnings date? Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Asterias Biotherapeutics. What price target have analysts set for AST? 2 analysts have issued 12-month price objectives for Asterias Biotherapeutics' shares. Their forecasts range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 372.2% from the stock's current price. View Analyst Ratings for Asterias Biotherapeutics. What is the consensus analysts' recommendation for Asterias Biotherapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Asterias Biotherapeutics stock? Here are some recent quotes from research analysts about Asterias Biotherapeutics stock: 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (7/10/2018) 2. HC Wainwright analysts commented, "We reiterate our Buy rating and 12-month price target of $11 on AST." (6/19/2018) Are investors shorting Asterias Biotherapeutics? Asterias Biotherapeutics saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 3,136,066 shares, a decrease of 22.5% from the June 15th total of 4,048,193 shares. Based on an average daily trading volume, of 398,001 shares, the short-interest ratio is presently 7.9 days. Approximately 9.6% of the company's shares are short sold. View Asterias Biotherapeutics' Current Options Chain. Who are some of Asterias Biotherapeutics' key competitors? Some companies that are related to Asterias Biotherapeutics include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF). Who are Asterias Biotherapeutics' key executives? Asterias Biotherapeutics' management team includes the folowing people: Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)Dr. Edward D. Wirth III, M.D., Ph.D., Chief Medical Officer (Age 53)Dr. Katharine E. Spink, Consultant (Age 44)Mr. Stephen L. Cartt, Advisor & Director (Age 55)Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42) Has Asterias Biotherapeutics been receiving favorable news coverage? Press coverage about AST stock has been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news sentiment score of 0.05 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 44.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of Asterias Biotherapeutics? Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Asterias Biotherapeutics' stock price today? One share of AST stock can currently be purchased for approximately $1.80. How big of a company is Asterias Biotherapeutics? Asterias Biotherapeutics has a market capitalization of $102.89 million. How can I contact Asterias Biotherapeutics? Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805. MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 75 (Vote Outperform)Underperform Votes: 67 (Vote Underperform)Total Votes: 142MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?